Answer to Question 1
Correct Answer: 2
Rationale 1: Monotherapy does not affect the duration of therapy.
Rationale 2: Monotherapy can lead to the development of resistant strains of bacteria.
Rationale 3: Monotherapy does not reduce the incidence of adverse effects.
Rationale 4: Bioavailability is associated with the route by which a drug is administered.
Global Rationale: Resistance develops quickly when aminoglycosides are administered as monotherapy. Resistance occurs when a species acquires an ability to degrade the antibiotic. Monotherapy does not shorten length of therapy and is not a strategy to reduce incidence of adverse effects. Monotherapy is not related to route of administration.
Answer to Question 2
Correct Answer: 2
Rationale 1: The concurrent use of acyclovir and gentamicin is not associated with vestibular toxicity.
Rationale 2: Concurrent use of gentamicin and acyclovir increases the risk of nephrotoxicity. A symptom of nephrotoxicity would be detected by monitoring kidney function tests.
Rationale 3: Acyclovir is not associated with ototoxicity.
Rationale 4: Visual disturbances are not associated with gentamicin therapy.
Global Rationale: Concurrent use of gentamicin and acyclovir increases the risk of nephrotoxicity. A symptom of nephrotoxicity would be detected by monitoring kidney function tests. Gentamycin alone can cause vertigo and ototoxicity, but these findings are not complicated by the addition of acyclovir. Visual acuity is not affected.
Gene Therapy of Parkinson’s Disease
Conditions Treated by Physical Therapy Cont
Nicotine replacement therapy: transdermal patch
Types of Policies Important for a Massage Therapy Practice
Gene therapy can prevent progression of metachromatic leukodystrophy
Antisense RNA and RNA interference (RNAi) approaches to silence genes for gene therapy